Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Prognostic Impact, Phenotypic and Molecular Characterization of Concordant and Discordant Bone Marrow Involvement in Patients with Diffuse Large b-Cell Lymphoma

Sara Alonso, MD, Miguel Alcoceba, Oscar Blanco, Julio Davila, MD, Juan Carlos Caballero, MD, Luis Garcia, Oscar Ferre, Felix Lopez-Cadenas, Nerea Arratibel, Alvaro Veiga, Monica Baile, Oriana Lopez, Estefania Perez, Maria Dolores Caballero, MD PhD, Marcos González, MD PhD, Consuelo Del Cañizo, MD PhD, Maria Belen Vidriales, MD PhD, Alejandro Martin, MD PhD

Blood (2015) 126 (23): 3871.

https://doi.org/10.1182/blood.V126.23.3871.3871

Published: 2015

Journal Articles

Peripheral Blood Analysis By Flow Cytometry for the Diagnosis of Type I Chronic Myelomonocytic Leukemia

Blood (2015) 126 (23): 5248.

https://doi.org/10.1182/blood.V126.23.5248.5248

Published: 2015

Journal Articles

Next Generation Flow (NGF) for High Sensitive Detection of Minimal Residual Disease (MRD) in Multiple Myeloma (MM)

Juan A Flores-Montero, MD, Bruno Paiva, PhD, Luzalba Sanoja-Flores, M.Sc., Noemi Puig, MD PhD, Omar García, PhD, Sebastian Böttcher, MD PD, José J Pérez-Morán, Maria Belen Vidriales, MD PhD, Maria-Victoria Mateos, Ramon Garcia-Sanz, MD PhD, Cristina Jimenez, BsC, Marcos González, MD PhD, Joaquin Martinez-López, MD PhD, María Consuelo Cañizo, MD PhD, Jesus San Miguel, MD PhD, Brian Durie, MD, Jacques J.M. van Dongen, Alberto Orfao, MD PhD

Blood (2015) 126 (23): 367.

https://doi.org/10.1182/blood.V126.23.367.367

Published: 2015

Journal Articles

Prognostic Value of Antigen Expression in Multiple Myeloma (MM): A Large GEM/Pethema Study Based in Four Consecutive Clinical Trials

Blood (2015) 126 (23): 19.

https://doi.org/10.1182/blood.V126.23.19.19

Published: 2015

Journal Articles

Comparison Between First-Generation 4-Color Vs. Second-Generation 8-Color Multiparameter Flow Cytometry (MFC) to Monitor Minimal Residual Disease (MRD) in Multiple Myeloma (MM)

Blood (2015) 126 (23): 2963.

https://doi.org/10.1182/blood.V126.23.2963.2963

Published: 2015

Journal Articles

Next Generation Flow (NGF): A High Sensitive Technique to Detect Circulating Peripheral Blood (PB) Clonal Plasma Cells (cPC) in Patients with Newly Diagnosed of Plasma Cell Neoplasms (PCN)

*Luzalba Sanoja-Flores, M.Sc., *Bruno Paiva, PhD, Juan A Flores-Montero, MD, Noemi Puig, MD PhD, Leire Burgos, Omar García, PhD, Felipe Prosper, MD, Juana Merino, MDPhD, Maria Belen Vidriales, MD PhD, Maria-Victoria Mateos, Ramon Garcia, MD, Luis Palomera, MDPhD, Rafael Rios, María Consuelo Cañizo, MD PhD, Brian G M Durie, Jacques J.M. van Dongen, Jesus San Miguel, MDPhD, Alberto Orfao, MD PhD

Blood (2015) 126 (23): 4180.

https://doi.org/10.1182/blood.V126.23.4180.4180

Published: 2015

Journal Articles

The Relevance of Minimal Residual Disease (MRD) Monitoring in Elderly Multiple Myeloma (MM) Patients

Blood (2015) 126 (23): 4181.

https://doi.org/10.1182/blood.V126.23.4181.4181

Published: 2015

Journal Articles

Clinical Impact of CD8+ Cells in Hodgkin Lymphoma Lymphadenopaties. Contribution of Flow Cytometry

Sara Alonso, MD, Maria Belen Vidriales, MD PhD, Maria Dolores Caballero, MD PhD, Oscar Blanco, J Galende, Maria Jesús Peñarrubia, MD PhD, Esther Zato, Abelardo Barez, Julio Davila, Juan Carlos Caballero, MD, Alberto Orfao, MD PhD, Marcos González, MD PhD, Ramon Garcia-Sanz, MD PhD

Blood (2015) 126 (23): 1442.

https://doi.org/10.1182/blood.V126.23.1442.1442

Published: 2015

Journal Articles

PD-1 and PD-L1 Are Overexpressed in the "Intermediate CD14+CD16+" and "Non Classical CD14lowCD16+" but Not in the "Classical CD14+CD16-" Monocytes in the Peripheral Blood of Chronic Myelomonocytic Leukemia

Hae Tha Mya, MRCP, FRCPath, Maria Diez Campelo, MD PhD, Sandra Valle Herrero, MD, Agustin Díaz-Alvarez, MDPhD, Domingo Bustos, MD, Luis M Vaquero, MD, José J Pérez, Verónica González, MD, Jose M Bastida, MD, Carlos Aguilar, MD, Abelardo Bárez, MD, Noemi Puig, MD PhD, Alejandro Martin-Sancho, MD PhD, María Jesús Garcia, Irene Aires, Sara Alonso, MD, Marcos González, MD PhD, Consuelo Del Cañizo, MD PhD, Maria Belen Vidriales, MD PhD

Blood (2015) 126 (23): 1694.

https://doi.org/10.1182/blood.V126.23.1694.1694

Published: 2015

Journal Articles

Prognostic Value of Immune Profiling Multiple Myeloma Patients during Minimal Residual Disease Monitoring in the Pethema/GEM2010MAS65 Study

Paula Arana, Bruno Paiva, PhD, Noemi Puig, MD PhD, Teresa Cedena, Lourdes Cordon, Maria Belen Vidriales, MD PhD, Joaquin Martinez-López, MDPhD, Enrique M. Ocio, MD PhD, Miguel T Hernandez, Ana Isabel Teruel, MD, Mercedes Gironella, M Asuncion Echeveste, Laura Rosiñol, MDPhD, Rafael Martinez, MDPhD, Albert Oriol, MDPhD, Joan Blade, MDPhD, Juan Jose Lahuerta, Maria-Victoria Mateos, Jesus San Miguel, MDPhD

Blood (2015) 126 (23): 721.

https://doi.org/10.1182/blood.V126.23.721.721

Published: 2015

Journal Articles

What Is the Frequency of Transplant-Eligible Multiple Myeloma Patients Being Cured? the Impact of an MGUS-like Signature at Diagnosis and MRD-Negativity

Bruno Paiva, PhD, Maria Belen Vidriales, MD PhD, Noemi Puig, MD PhD, Teresa Cedena, Lourdes Cordon, Maria-Victoria Mateos, Joaquin Martinez-López, MDPhD, Laura Rosiñol, MDPhD, Alfonso Garcia de Coca, MD PhD, Natalia De Las Heras, MD, Josefina Galende, Jose Mariano Hernandez, MD, Luis Palomera, MDPhD, Javier De La Rubia, Joan Blade, MDPhD, Jesus San Miguel, MDPhD, Juan Jose Lahuerta

Blood (2015) 126 (23): 725.

https://doi.org/10.1182/blood.V126.23.725.725

Published: 2015

Journal Articles

Low-Dose Dexamethasone Does Not Abrogate the Immunomodulatory Effects of Lenalidomide and Both Reactivate the Impaired Immune System of High-Risk Smoldering Multiple Myeloma Patients

Blood (2015) 126 (23): 2955.

https://doi.org/10.1182/blood.V126.23.2955.2955

Published: 2015

Journal Articles

Clinical Significance of Sensitive Flow-MRD Monitoring in Elderly Multiple Myeloma Patients on the Pethema/GEM2010MAS65 Trial

Blood (2014) 124 (21): 3390.

https://doi.org/10.1182/blood.V124.21.3390.3390

Published: 2014

Journal Articles

Defining the Differentiation Stage of Multiple Myeloma Plasma Cells: Biological and Clinical Significance

Blood (2014) 124 (21): 25.

https://doi.org/10.1182/blood.V124.21.25.25

Published: 2014

Journal Articles

Phenotypic, Transcriptomic and Genomic Characterization Of Clonal Plasma Cells (PCs) From Newly Diagnosed Patients With Light Chain Amyloidosis (AL)

Blood (2013) 122 (21): 1841.

https://doi.org/10.1182/blood.V122.21.1841.1841

Published: 2013

Journal Articles

Minimal Residual Diease Evaluation By Flow Cytometry Is a Complementary Tool To Cytogenetics For Treatment Decision In Acute Myeloid Leukemia

Blood (2013) 122 (21): 2576.

https://doi.org/10.1182/blood.V122.21.2576.2576

Published: 2013

Journal Articles

Genomic Comparison Of Clonal B-Cells In Waldenstrom Macroglobulinemia (WM) Versus IgM MGUS

Blood (2013) 122 (21): 400.

https://doi.org/10.1182/blood.V122.21.400.400

Published: 2013

Journal Articles

Phenotypic and Genomic Analysis Of Multiple Myeloma (MM) Minimal Residual Disease (MRD) Clonal Plasma Cells (PCs)

Blood (2013) 122 (21): 402.

https://doi.org/10.1182/blood.V122.21.402.402

Published: 2013

Journal Articles

Proteasome Inhibitor Bortezomib Has Antitumour Activity Against Both CD34 Negative and CD34 Positive Acute Myeloid Leukemia Cells.

Enrique Colado, MD, Jesus Martin, MD, Maria-Belen Vidriales, MD,PhD, Atanasio Pandiella, MD,PhD, Dixie-Lee Esseltine, MD,FRCPC, Jose J. Perez, Enrique M. Ocio, MD,PhD, J.F. San Miguel, MD,PhD

Blood (2006) 108 (11): 1989.

https://doi.org/10.1182/blood.V108.11.1989.1989

Published: 2006

Journal Articles

Minimal Residual Disease (MRD) Evaluation by Flow Cytometry in Acute Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.

Maria-Belen Vidriales, MD, PhD, Jose J. Pérez, Consuelo López-Berges, MD, PhD, Norma C. Gutierrez, MD, PhD, Juana Ciudad, PhD, Lourdes Vazquez, MD, PhD, Consuelo del Cañizo, MD, PhD, Joaquín Díaz-Mediavilla, MD, PhD, Javier Fernández-Calvo, MD, Fernando Ramos, MD, PhD, María Jesús Rodriguez, MD, PhD, María José Calmuntia, MD, PhD, Alberto Orfao, MD, PhD, Jesús San Miguel, MD, PhD

Blood (2004) 104 (11): 1103.

https://doi.org/10.1182/blood.V104.11.1103.1103

Published: 2004

NARROW

Prognostic Impact, Phenotypic and Molecular Characterization of Concordant and Discordant Bone Marrow Involvement in Patients with Diffuse Large b-Cell Lymphoma

Peripheral Blood Analysis By Flow Cytometry for the Diagnosis of Type I Chronic Myelomonocytic Leukemia

Next Generation Flow (NGF) for High Sensitive Detection of Minimal Residual Disease (MRD) in Multiple Myeloma (MM)

Prognostic Value of Antigen Expression in Multiple Myeloma (MM): A Large GEM/Pethema Study Based in Four Consecutive Clinical Trials

Comparison Between First-Generation 4-Color Vs. Second-Generation 8-Color Multiparameter Flow Cytometry (MFC) to Monitor Minimal Residual Disease (MRD) in Multiple Myeloma (MM)

Next Generation Flow (NGF): A High Sensitive Technique to Detect Circulating Peripheral Blood (PB) Clonal Plasma Cells (cPC) in Patients with Newly Diagnosed of Plasma Cell Neoplasms (PCN)

The Relevance of Minimal Residual Disease (MRD) Monitoring in Elderly Multiple Myeloma (MM) Patients

Clinical Impact of CD8+ Cells in Hodgkin Lymphoma Lymphadenopaties. Contribution of Flow Cytometry

PD-1 and PD-L1 Are Overexpressed in the "Intermediate CD14+CD16+" and "Non Classical CD14lowCD16+" but Not in the "Classical CD14+CD16-" Monocytes in the Peripheral Blood of Chronic Myelomonocytic Leukemia

Prognostic Value of Immune Profiling Multiple Myeloma Patients during Minimal Residual Disease Monitoring in the Pethema/GEM2010MAS65 Study

What Is the Frequency of Transplant-Eligible Multiple Myeloma Patients Being Cured? the Impact of an MGUS-like Signature at Diagnosis and MRD-Negativity

Low-Dose Dexamethasone Does Not Abrogate the Immunomodulatory Effects of Lenalidomide and Both Reactivate the Impaired Immune System of High-Risk Smoldering Multiple Myeloma Patients

Clinical Significance of Sensitive Flow-MRD Monitoring in Elderly Multiple Myeloma Patients on the Pethema/GEM2010MAS65 Trial

Defining the Differentiation Stage of Multiple Myeloma Plasma Cells: Biological and Clinical Significance

Phenotypic, Transcriptomic and Genomic Characterization Of Clonal Plasma Cells (PCs) From Newly Diagnosed Patients With Light Chain Amyloidosis (AL)

Minimal Residual Diease Evaluation By Flow Cytometry Is a Complementary Tool To Cytogenetics For Treatment Decision In Acute Myeloid Leukemia

Genomic Comparison Of Clonal B-Cells In Waldenstrom Macroglobulinemia (WM) Versus IgM MGUS

Phenotypic and Genomic Analysis Of Multiple Myeloma (MM) Minimal Residual Disease (MRD) Clonal Plasma Cells (PCs)

Proteasome Inhibitor Bortezomib Has Antitumour Activity Against Both CD34 Negative and CD34 Positive Acute Myeloid Leukemia Cells.

Minimal Residual Disease (MRD) Evaluation by Flow Cytometry in Acute Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only